Diagnostic accuracy evaluation of individual or combinational fecal immunochemical test, M3 gene, KRAS mutation and tumor methylation burden in colorectal carcinoma

结直肠癌中粪便免疫化学检测、M3基因、KRAS突变和肿瘤甲基化负荷的单独或联合诊断准确性评估

阅读:2

Abstract

OBJECTIVE: This study is aimed to develop multivariate prediction method in colorectal cancer (CRC) diagnosis. METHODOLOGY: M3 gene expression was determined using Fecal DNA extraction kits and performed by qRT-PCR. Methylation-burden and KRAS-mutation were detected by using the corresponding kits. Receiver operating characteristic curve analysis and the area under the curve (AUC) was calculated to evaluate diagnostic performance using SPSS software. RESULTS: 197 of CRC samples were enrolled to screen the best predictive combination among fecal immunochemical test (FIT), M3 expression and KRAS-mutation in feces, and Methylation-burden in blood. Single factor analysis showed that M3 expression showed the best diagnosis performance and fecal immunochemical test (FIT) showed the lowest AUC. Combination of two makers universally enhanced diagnostic performance, of which Methylation-burden and M3 alliance displayed the highest AUC value. Interestingly, combination of M3, Methylation-burden and KRAS-mutation reached the best performance for all patients (AUC: 0.920), especially for early CRC patients (AUC: 0.931), which possessed the same predictive efficiency with the combination of four factors. CONCLUSION: Combined application of M3, Methylation-burden and KRAS-mutation might be the most reliable method for early CRC diagnosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。